Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment
Company has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma.
- Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment
Company has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma.
- GRAS Status Affirmed for Lipogen Phosphatidylserine
Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line.
- GRAS Status Affirmed for Lipogen Phosphatidylserine
Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line.
- GRAS Status Affirmed for Lipogen Phosphatidylserine
Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line.
- GRAS Status Affirmed for Lipogen Phosphatidylserine
Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims
At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act.
- FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims
At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act.
- FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims
At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act.
- FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims
At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act.
- FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims
At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act.
- DEA: Hi-Tech Pharmaceuticals & 11 Individuals Indicted for "Generic" Pill Fraud Scheme
Hi-Tech Pharmaceuticals & 11 Individuals have been indicted by a federal grand jury on multiple felony charges relating to a scheme to sell adulterated and unapproved new drugs over the internet.
- DEA: Hi-Tech Pharmaceuticals & 11 Individuals Indicted for "Generic" Pill Fraud Scheme
Hi-Tech Pharmaceuticals & 11 Individuals have been indicted by a federal grand jury on multiple felony charges relating to a scheme to sell adulterated and unapproved new drugs over the internet.
- Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP
Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application.
- Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP
Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application.
- Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP
Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application.
- Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP
Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application.
- Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP
Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application.
- Ontario Government Closer to Regulating Traditional Chinese Medicine
Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading.
- Ontario Government Closer to Regulating Traditional Chinese Medicine
Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading.
- Ontario Government Closer to Regulating Traditional Chinese Medicine
Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- Allimax Nutraceuticals US starts clinical trial for treating Lyme disease
Allimax Nutraceuticals US, in conjunction with the Health Healing and Hope Foundation, have started their Lyme disease double blind clinical study being conducted in Texas by Dr.’s Joan Vandergriff ND, Hamid Moayad DO, William Keller Ph.D., Hugo Rodier M.D.
- Allimax Nutraceuticals US starts clinical trial for treating Lyme disease
Allimax Nutraceuticals US, in conjunction with the Health Healing and Hope Foundation, have started their Lyme disease double blind clinical study being conducted in Texas by Dr.’s Joan Vandergriff ND, Hamid Moayad DO, William Keller Ph.D., Hugo Rodier M.D.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Indian Food Safety and Standards Bill 2005 signed into law.
GCI Nutrients-India reports that the Indian Food Safety and Standards Bill 2005 was recently signed into law by the President of India.
- Indian Food Safety and Standards Bill 2005 signed into law.
GCI Nutrients-India reports that the Indian Food Safety and Standards Bill 2005 was recently signed into law by the President of India.
- NHPD October 2006 Monthly Communiqué Available
The NHPD Monthly Communiqué, October 2006 (Vol. 2, Issue 2), is now available online.
- NHPD October 2006 Monthly Communiqué Available
The NHPD Monthly Communiqué, October 2006 (Vol. 2, Issue 2), is now available online.
- NHPD October 2006 Monthly Communiqué Available
The NHPD Monthly Communiqué, October 2006 (Vol. 2, Issue 2), is now available online.
- Talks Ongoing: Trans-Tasman regulatory scheme
A second phase of consultation on the proposed trans-Tasman regulatory scheme for therapeutic products is now underway and feedback is being invited.
- Talks Ongoing: Trans-Tasman regulatory scheme
A second phase of consultation on the proposed trans-Tasman regulatory scheme for therapeutic products is now underway and feedback is being invited.
- United Natural Products Alliance (UNPA) Statement On The Status of Federal Dietary Supplement Serious Adverse Event Reporting Legislation
UNPA will continue to work aggressively for passage of the Non-Prescription Drug and Dietary Supplement Consumer Protection Act (S.3546/H.R.6168) when the Congress reconvenes for a brief “lame duck” session the week after the November elections.
- United Natural Products Alliance (UNPA) Statement On The Status of Federal Dietary Supplement Serious Adverse Event Reporting Legislation
UNPA will continue to work aggressively for passage of the Non-Prescription Drug and Dietary Supplement Consumer Protection Act (S.3546/H.R.6168) when the Congress reconvenes for a brief “lame duck” session the week after the November elections.
- United Natural Products Alliance (UNPA) Statement On The Status of Federal Dietary Supplement Serious Adverse Event Reporting Legislation
UNPA will continue to work aggressively for passage of the Non-Prescription Drug and Dietary Supplement Consumer Protection Act (S.3546/H.R.6168) when the Congress reconvenes for a brief “lame duck” session the week after the November elections.
- United Natural Products Alliance (UNPA) Statement On The Status of Federal Dietary Supplement Serious Adverse Event Reporting Legislation
UNPA will continue to work aggressively for passage of the Non-Prescription Drug and Dietary Supplement Consumer Protection Act (S.3546/H.R.6168) when the Congress reconvenes for a brief “lame duck” session the week after the November elections.
- Advisory - Health Canada advises consumers not to use four unauthorized natural health products that claim to treat serious diseases
Health Canada is advising consumers not to use four unauthorized natural health products, Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules, that are promoted to treat serious health conditions such as cancer, arthritis and heart disease because such unapproved health claims are in violation of the Food and Drugs Act.
- Advisory - Health Canada advises consumers not to use four unauthorized natural health products that claim to treat serious diseases
Health Canada is advising consumers not to use four unauthorized natural health products, Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules, that are promoted to treat serious health conditions such as cancer, arthritis and heart disease because such unapproved health claims are in violation of the Food and Drugs Act.
- Advisory - Health Canada advises consumers not to use four unauthorized natural health products that claim to treat serious diseases
Health Canada is advising consumers not to use four unauthorized natural health products, Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules, that are promoted to treat serious health conditions such as cancer, arthritis and heart disease because such unapproved health claims are in violation of the Food and Drugs Act.
- Plant sterols and formulated beverages now approved
New standards allow Australians and New Zealanders to have access to a range of foods enriched with plant sterols, and allow manufacturers to make formulated beverages in Australia, not just New Zealand.
- Plant sterols and formulated beverages now approved
New standards allow Australians and New Zealanders to have access to a range of foods enriched with plant sterols, and allow manufacturers to make formulated beverages in Australia, not just New Zealand.
- SelenoExcell® Receives Independent GRAS Evaluation
Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories.
- SelenoExcell® Receives Independent GRAS Evaluation
Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories.
- SelenoExcell® Receives Independent GRAS Evaluation
Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories.
- SelenoExcell® Receives Independent GRAS Evaluation
Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories.
- SelenoExcell® Receives Independent GRAS Evaluation
Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories.
- SelenoExcell® Receives Independent GRAS Evaluation
Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts
Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
Health Canada has issued a notice regarding its approach to the refusal of Product License Applications. The approach is posted at http://www.hc-sc.gc.ca/dhp-mps/prodnatur/bulletins/pl-ref-lp_e.html .
Summary:
If a product licence application (PLA) has been refused by the Natural Health Products Directorate, the submission number associated with that product becomes invalid. The Notice of Refusal issued to the applicant will indicate the reason(s) for the refusal and will also make reference to compliance and enforcement actions applied by Health Canada.
Unapproved natural health products (NHPs) that are for sale in Canada and have had their product licence applications refused will be subject to compliance action in accordance with the Compliance Policy for Natural Health Products. In the event that an application is refused due to concerns with the product's safety, efficacy and/or quality, the applicant must stop sale and recall the product from the market or face immediate compliance and enforcement action.
In accordance with section 9(2) of the Natural Health Products Regulations, applicants receiving a Notice of Refusal have 30 days to appeal the decision and request that their application be reinstated. Should applicants fail to submit their appeal within the 30-day timeframe or, if following a review of the appeal, the refusal of the application stands, the compliance and enforcement approach described above will be applied.
Applicants intending to resubmit a product licence application are encouraged to carefully read the Notice of Refusal and ensure that the issues which lead to the refusal of their initial application are addressed in their new product licence application or else it will also be refused.
Applicants should refer to the following table for information on what constitutes a "complete" product licence application: Information Requirements for Product Licensing |